Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.52 |
| ▸ | DHFR | P00374 | 1/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16210333 | 0.90 | TMEM97 (0.53) | TMEM97SIGMAR1DHFRPTGDR2KDR | |
| SCHEMBL16210173 | 0.89 | TMEM97 (0.52) | TMEM97SIGMAR1DHFRPTGDR2KDR | |
| SCHEMBL16379829 | 0.88 | DHFR (0.50) | TMEM97SIGMAR1DHFRPTGDR2KDR | |
| SCHEMBL16220574 | 0.88 | DHFR (0.50) | TMEM97SIGMAR1DHFRPTGDR2KDR | |
| SCHEMBL3338693 | 0.87 | TMEM97 (0.48) | TMEM97SIGMAR1DHFRPTGDR2KDR | |
| SCHEMBL16217180 | 0.87 | TMEM97 (0.50) | TMEM97SIGMAR1DHFRPTGDR2KDR | |
| SCHEMBL16210567 | 0.85 | DHFR (0.48) | TMEM97SIGMAR1DHFRPTGDR2KDR | |
| SCHEMBL16210500 | 0.83 | PTGDR2 (0.49) | TMEM97SIGMAR1DHFRPTGDR2KDR | |
| SCHEMBL30902147 | 0.83 | PTGDR2 (0.51) | TMEM97SIGMAR1DHFRPTGDR2 | |
| SCHEMBL1831787 | 0.82 | MEN1 (0.50) | TMEM97SIGMAR1DHFRPTGDR2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991989-B1 | IMIDAZO-TRIAZINE DERIVATIVES AS PDE10 INHIBITORS | PFIZER (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9296761-B2 | Triazine derivatives | PFIZER INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296761-B2 | Triazine derivatives | PFIZER INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150353579-A1 | Triazine Derivatives | PFIZER (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353579-A1 | Triazine Derivatives | PFIZER (US) | 2015-12-10 | — | — | US | disclosed |
| US-9145427-B2 | Triazine derivatives | PFIZER INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145427-B2 | Triazine derivatives | PFIZER INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20150080401-A1 | Triazine Derivatives | PFIZER (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080401-A1 | Triazine Derivatives | PFIZER (US) | 2015-03-19 | — | — | US | disclosed |
| US-8933224-B2 | Triazine derivatives | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933224-B2 | Triazine derivatives | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140329820-A1 | Triazine Derivatives | PFIZER INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329820-A1 | Triazine Derivatives | PFIZER INC. (US) | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329820-A1 | Triazine Derivatives | PDE12, PDE5A, PDE10A | TMEM97 3393/4885SIGMAR1 573/4885DHFR 388/4885 |
| US-20150353579-A1 | Triazine Derivatives | PDE12, PDE5A, PDE10A | TMEM97 3393/4885SIGMAR1 573/4885DHFR 388/4885 |
| US-20150080401-A1 | Triazine Derivatives | PDE12, PDE5A, PDE10A | TMEM97 3393/4885SIGMAR1 573/4885DHFR 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.